Guardant Health is a precision oncology company that develops blood and tissue-based diagnostic tests for cancer detection and tumor profiling. The company's test portfolio includes liquid biopsy assays measuring hundreds of genes to identify cancer-related mutations, a colorectal cancer screening test, and research tools for analyzing tumor characteristics and immune responses. Beyond testing services, Guardant Health provides development support for companion diagnostics, clinical study management, and software platforms that integrate patient data with clinical research opportunities.
1Y: 178.80 (+92.2%) · range 78.60–187.22
entry readiness 5 · NOT READY · exit proximity 15
Value area 143.75–183.17 · 5% of 120d volume overhead · clean runway
| Source | Score | Last seen |
|---|---|---|
| congressional-trading | 0.095 | Oct 30, 2026 |
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -3.57% | +0.50% | mature |
| 40d | -3.86% | +1.75% | mature |